Novo Nordisk A/S
- Open
- 48.69
- Day high
- 49.38
- Day low
- 48.58
- Prev close
- 48.89
- Volume
- 5.0M
- Mkt cap
- $218.2B
- P/E (TTM)
- 11.7
- EPS (TTM)
- $4.19
- P/B
- 7.0
- P/S
- 4.4
- Yield
- 2.72%
- Per share
- $1.33
Novo Nordisk A/S (NVO) is a Healthcare company listed on NYSE. The stock is down 30% over the past year. Drillr has 4 published research articles covering NVO.
Novo Nordisk A/S (NVO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NVO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.87 | $1.04 | +19.5% | $11.0B | +1.5% |
| Feb 4, 2026 | $0.90 | $1.00 | +11.1% | $12.3B | +3.4% |
| Nov 5, 2025 | $0.77 | $1.02 | +32.5% | $11.8B | -4.8% |
| Aug 6, 2025 | $0.93 | $0.97 | +4.3% | $12.1B | -1.4% |
| May 7, 2025 | $0.92 | $0.92 | +0.0% | $11.5B | -3.8% |
| Feb 5, 2025 | $0.88 | $0.91 | +3.4% | $11.9B | +2.7% |
| May 2, 2024 | $0.74 | $0.82 | +10.5% | $9.4B | +3.4% |
| Jan 31, 2024 | $0.65 | $0.71 | +9.5% | $9.7B | +6.2% |
| Nov 2, 2023 | $0.71 | $0.71 | +0.0% | $8.3B | +1.4% |
| Aug 10, 2023 | $0.67 | $0.63 | -6.0% | $7.9B | -3.3% |
| May 4, 2023 | $0.63 | $0.63 | +0.0% | $7.8B | +1.6% |
| Feb 1, 2023 | $0.41 | $0.41 | +0.0% | $6.9B | +1.6% |
NVO research & analysis
VKTX Falls 25% on Weight-Loss Drug Safety Data, Hits LLY and NVO
Viking Therapeutics dropped 25% on new weight-loss drug safety data. What the GLP-1 cohort spillover means for LLY, NVO, AMGN.
VKTXLLYAMGNLLY Stock Dips on Foundayo Approval — Is the GLP-1 Oral Drug a NVO Killer?
Eli Lilly's shares fell despite Foundayo (orforglipron) FDA approval due to geopolitical tensions, but the oral GLP-1's no-restrictions profile positions it to challenge Novo's injectable dominance. LLY's stellar growth (45% revenue surge) contrasts Novo's slowdown (-5-13% 2026 guidance), making the dip a potential entry point. Watch initial uptake and competitive filings for share shifts.
LLYLLY FDA Approval: Oral Obesity Pill Foundayo Threatens NVO's Wegovy as Revenue Surges 45%
FDA approval of Lilly's oral obesity pill Foundayo (orforglipron) intensifies rivalry with Novo's Wegovy, with Lilly's superior growth and oral convenience poised to capture needle-averse patients. NVO's guidance cuts highlight vulnerabilities, favoring LLY overweight amid 45% revenue surge vs. NVO's 6%. Key: Q1 2026 uptake and Medicare dynamics.
LLYFTC Insulin Crackdown: CVS Settles — What It Means for LLY, NVO, and WBA
CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.
CVSWBALLY
Novo Nordisk A/S company profile
Overview
Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company founded in 1923 and headquartered in Bagsvaerd, Denmark. The company has evolved from its origins as an insulin manufacturer into a global leader in diabetes care and, more recently, obesity treatment. Novo Nordisk went public in 1981 and has grown to serve over 45 million patients worldwide with diabetes and obesity treatments. The company operates primarily through two business segments: Diabetes and Obesity Care, and Rare Disease, with the former representing the vast majority of its revenue and growth trajectory.
Business
Novo Nordisk operates in the pharmaceutical industry, specializing in treatments for chronic diseases, particularly diabetes, obesity, and rare disorders. The company's core business revolves around developing, manufacturing, and distributing prescription medications and medical devices. The Diabetes and Obesity Care segment represents approximately 90% of total revenue and focuses on treatments for metabolic disorders. This segment's flagship products include GLP-1 receptor agonists - a class of medications that mimic hormones naturally produced in the intestine to regulate blood sugar and appetite. Key products include Ozempic and Rybelsus (semaglutide) for diabetes treatment, and Wegovy (also semaglutide but at higher doses) for obesity management. GLP-1 medications work by slowing gastric emptying, stimulating insulin release when blood sugar is elevated, and reducing appetite, making them effective for both diabetes control and weight loss. The segment also includes traditional insulin products and delivery devices like insulin pens and smart injection systems. The Rare Disease segment accounts for approximately 10% of revenue and focuses on treatments for uncommon conditions including rare blood disorders (such as hemophilia), rare endocrine disorders, and hormone replacement therapies. This segment includes products like growth hormone treatments and clotting factor therapies for bleeding disorders. The company also manufactures and distributes medical devices including insulin pens, growth hormone pens, and injection needles, as well as digital health solutions like smart insulin pens and dose guidance applications to support patient treatment adherence.
Revenue model
Novo Nordisk generates revenue primarily through direct product sales to healthcare systems, pharmacies, and distributors globally. The company sells prescription medications that require healthcare provider authorization, with patients and insurance systems serving as the ultimate paying customers. The business model relies heavily on patent-protected innovative therapies that command premium pricing. GLP-1 treatments like Ozempic and Wegovy represent high-value products with significant pricing power due to their clinical efficacy and limited competition. The company also generates recurring revenue from consumable medical devices and supplies that accompany their drug therapies. Revenue growth drivers include expanding patient populations (particularly in obesity treatment where market penetration remains low), geographic expansion into new markets, and lifecycle management through new formulations and indications for existing drugs. The company has been investing heavily in manufacturing capacity to meet growing demand, particularly for GLP-1 treatments. Factors that could increase margins include economies of scale from higher production volumes, successful launch of next-generation treatments with superior efficacy, and expansion into higher-margin rare disease markets. Margin pressures could arise from increased competition as patents expire, pricing pressure from government healthcare systems and insurance providers, higher manufacturing costs due to complex biologics production, and significant R&D investments required to maintain innovation leadership. The company also faces potential margin compression from compounded versions of their products and regulatory changes affecting drug pricing, particularly in key markets like the United States.
Competitive moat
Novo Nordisk possesses a strong competitive moat built on multiple reinforcing factors. The company's primary moat stems from its deep scientific expertise and patent portfolio in metabolic diseases, particularly around GLP-1 receptor agonists where it maintains technological leadership. This expertise creates high barriers to entry as developing competing biologics requires substantial investment, clinical trial expertise, and regulatory navigation that can take over a decade. The company benefits from significant switching costs as patients and physicians develop familiarity with specific treatment regimens, and changing diabetes or obesity medications involves clinical risk and adjustment periods. Additionally, Novo Nordisk has built strong relationships with healthcare providers and established comprehensive patient support programs that create customer loyalty. Regulatory barriers provide another layer of protection, as new entrants must navigate complex approval processes for biologics, and biosimilar competition faces additional hurdles compared to generic small-molecule drugs. The company's manufacturing expertise in complex biologics production also creates operational barriers for competitors. However, the moat faces potential threats from large pharmaceutical companies developing competing GLP-1 treatments (such as Eli Lilly's tirzepatide), potential future breakthrough technologies that could disrupt current treatment paradigms, and the growing threat of compounded versions of semaglutide that bypass traditional regulatory protections. Additionally, as patents expire over the next decade, biosimilar competition will likely intensify, potentially eroding pricing power and market share. The company's continued investment in next-generation treatments and pipeline development will be critical to maintaining its competitive advantages.
Risks & safety
Novo Nordisk demonstrates a strong margin of safety with solid financial fundamentals, though some metrics warrant attention. • Liquidity and Solvency: Cash and short-term investments of $2.2 billion against current liabilities of $30.3 billion creates a current ratio of 0.74, indicating potential short-term liquidity constraints. However, strong operating cash flow of $16.9 billion in 2024 provides substantial cash generation capability. • Debt Position: Debt-to-equity ratio of 0.72 represents moderate leverage levels that appear manageable given the company's cash flow generation and stable business model. • Valuation Metrics: Trading at 27.3x P/E ratio and 19.2x price-to-book, indicating premium valuation that reflects growth expectations but may limit downside protection. EV/EBITDA of 20.7x suggests the market is pricing in continued strong growth. • Profitability: Strong return on equity of 70% and healthy EBITDA margins demonstrate robust profitability and efficient capital allocation. • Other Considerations: Free cash flow of $9.7 billion provides substantial financial flexibility, while the company's dominant market position in growing therapeutic areas supports earnings stability.
Recent development
Over the past few years, Novo Nordisk has undergone a significant strategic transformation, evolving from primarily a diabetes-focused company to a leader in both diabetes and obesity treatment. The company's GLP-1 franchise expansion represents the most significant development, with Wegovy (semaglutide for obesity) driving 57% growth in the obesity care segment in 2024. Key strategic initiatives include substantial manufacturing capacity expansion, highlighted by the acquisition of three Catalent manufacturing sites to address supply constraints and meet growing demand. The company has been investing heavily in production infrastructure, with capital expenditures reaching approximately $65 billion DKK in 2024. Pipeline advancement has been particularly notable with multiple next-generation obesity treatments progressing through clinical trials. CagriSema, a combination therapy showing up to 22.7% weight loss in trials, represents a potential breakthrough treatment. The company has also advanced oral semaglutide formulations and is developing amycretin, a dual GLP-1/glucagon receptor agonist showing promising weight loss results. The company has expanded its digital health capabilities through smart insulin pens and dose guidance applications, while also pursuing strategic partnerships and acquisitions to strengthen its pipeline. Recent developments include in-licensing early-stage obesity assets and collaborations in the cardiometabolic space. Market access expansion has been a key focus, with Wegovy now covering 55 million people in the U.S. and expanded Medicaid coverage. The company has also been actively combating compounded versions of its products while working to improve patient access through programs like NovoCare pharmacy and telehealth collaborations.
NVO company profile · for informational purposes only — not investment advice.
Track NVO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free